TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06645912

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral nutritional supplement
Description: The ONS group received a high-protein ONS providing 18.8 g of protein, 7 g of fat, 28 g of carbohydrates, and 250 calories of energy per 200 mL and medical nutrition therapy. The product is gluten-free and contains lactose, minerals, trace elements, and vitamins . The Control group received only standard nutrition therapy without ONS supplementation.
Study: NCT04645602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Pill taken by mouth, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous injection through a vein (IV).
Study: NCT06649500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill
Description: The Walker View system is a treadmill equipped with a loaded cell sensor belt and a 3D camera that allows you to detect every single angular movement of the subject. Furthermore, thanks to the two optics, a classic one for 2D shooting in high resolution, and a revolutionary one for infrared rays, it is possible to reconstruct the position of the subject in space in three-dimensional mode and in real time. The reflected image reconstructed by the system helps to improve movement through the \&#34;continuous feedback system\&#34; method.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: Conventional therapy intervention will follow the usual treatment according to current clinical practice. This treatment will be delivered to patients in a group session in order the balance disorders.
Study: NCT06649084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent Lexical Retrieval Training (Multi-LRT)
Description: In person or via teletherapy: A multi-component treatment incorporating elements of restitutive, compensatory, and care-partner focused interventions. Participants work on producing names of personally relevant target in multiple communication modalities. Treatment focuses on the use of strategies which capitalize on residual linguistic ability and autobiographical memory to support word retrieval. The participant completes two one-hour-long sessions per week plus daily homework. The participant also meets 4 times during the course of treatment with a study partner (e.g., spouse) for communication counseling, education, and practice of communication strategies.
Study: NCT05651542

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Self-Management Intervention
Description: In addition to standard care, participants receive content on self-management which includes cognitive behavioral therapy, relaxation, and diet. Weekly phone calls provide support for achieving the sessions goals.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The control group will receive standard care.
Study: NCT06212765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: to take 1 pod a day for 45 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-citrulline
Description: to take 1 pod a day for 45 days
Study: NCT05809726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual lymph drainage
Description: one session 20 minutes

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Manual lymph drainage
Description: one session 20 minutes
Study: NCT05764642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity
Description: Ultrasound contrast agent administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Definity
Description: Ultrasound contrast agent administered intravenously

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Super-resolution ultrasound imaging
Description: Imaging technology for microvessel imaging. This technology localizes and tracks individual microbubbles (FDA approved ultrasound contrast agents) to map microvessel morphology and flow speed at a spatial resolution about 10 times higher than conventional ultrasound imaging.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Super-resolution ultrasound imaging
Description: Imaging technology for microvessel imaging. This technology localizes and tracks individual microbubbles (FDA approved ultrasound contrast agents) to map microvessel morphology and flow speed at a spatial resolution about 10 times higher than conventional ultrasound imaging.
Study: NCT06530498

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of the severity of hirsutism using the visual modified Ferriman-Gallwey scale
Description: Assessment of the severity of hirsutism using the visual modified Ferriman-Gallwey scale in 9 body regions rated from 0 (no growth of terminal hair) to 4 (extensive hair growth), thus with a score ranging from 0 (the lowest score - no hirsutism) to 36 points (the highest score - the greatest severity of hirsutism)

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of the severity of hirsutism using the visual modified Ferriman-Gallwey scale
Description: Assessment of the severity of hirsutism using the visual modified Ferriman-Gallwey scale in 9 body regions rated from 0 (no growth of terminal hair) to 4 (extensive hair growth), thus with a score ranging from 0 (the lowest score - no hirsutism) to 36 points (the highest score - the greatest severity of hirsutism)

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of the severity of endogenetic alopecia using the visual Ludwig Scale
Description: Visual assessment of baldness on the Ludwig scale from I (least severe baldness) to III (most severe baldness):~Type I - minimal thinning of the mid-line parting in the hair; Type II - gradual thinning and noticeable widening of the mid-line parting in the hair; Type III - Heavy to total thinning of the mid-line

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of the severity of endogenetic alopecia using the visual Ludwig Scale
Description: Visual assessment of baldness on the Ludwig scale from I (least severe baldness) to III (most severe baldness):~Type I - minimal thinning of the mid-line parting in the hair; Type II - gradual thinning and noticeable widening of the mid-line parting in the hair; Type III - Heavy to total thinning of the mid-line
Study: NCT06649084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent Video Implemented Script Training in Aphasia (Multi-VISTA)
Description: In person or via teletherapy: A multi-component treatment incorporating elements of restitutive, compensatory, and care-partner focused interventions. Participants work on producing personally relevant scripts of 3-5 sentences in length. Length and complexity of scripts are individually tailored. The participant completes 30 minutes per day of home practice, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts. Biweekly (one hour each) sessions with a clinician are held which target clear and accurate script production, script memorization, and conversational usage of the script and multimodal communication. The participant also meets 6 times during the course of treatment with a study partner (e.g., spouse) for communication counseling, education, and practice of communication strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent Communication Partner Training (Multi-CPT)
Description: In person or via teletherapy: A multi-component treatment incorporating elements of compensatory and care-partner focused interventions. Biweekly (one hour each) sessions with a clinician are held which target use of communication strategies including multimodal communication for the participant and study partner (e.g., spouse). The participant also completes regular assignments meant to increase generalization of communication strategies and progress on personal goals.
Study: NCT05745207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086
Description: E2086 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086
Description: E2086 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086
Description: E2086 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086
Description: E2086 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086
Description: E2086 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086
Description: E2086 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086
Description: E2086 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086
Description: E2086 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2086 matched placebo tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2086 matched placebo tablets.
Study: NCT06645847

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ketone ester
Description: * 37.5 mL tropical flavored KE beverage containing 12.5 g/day of ketone ester will be consumed for the first 7 days, with the first meal of the day.~* 75 mL tropical flavored KE beverage containing 25 g/day of ketone ester will be consumed for week 2 (for 1 week) also with the first meal of the day.~* 112.5 mL tropical flavored KE beverage containing 37.5g/day of ketone ester will be consumed from week 3 (for 1 week). 25g (75mL) with the first meal of the day and 12.5g (37.5mL) with the last meal of the day.~* 150 mL tropical flavored KE beverage containing 50g/day of ketone ester will be consumed from week 4 (for 17 week). 25g (75mL) with the first meal of the day and 25g (75mL) with the last meal of the day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Non-ketone placebo
Description: * 37.5 mL tropical flavored, non-ketogenic canola oil, beverage containing 12.5 g/day of canola oil will be consumed for the first 7 days, with the first meal of the day.~* 75 mL (25 g/day) of canola oil will be consumed at week 2 (for 1 week) also with the first meal of the day.~* 112.5 mL (37.5g/day) of canola oil will be consumed from week 3 (for 1 week). 25g (75mL) with the first meal of the day and 12.5g (37.5mL) with the last meal of the day.~* 150 mL (50g/day) of canola oil will be consumed from week 4 (for 17 week). 25g (75mL) with the first meal of the day and 25g (75mL) with the last meal of the day.
Study: NCT05745207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2086 matched placebo tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2086 matched placebo tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2086 matched placebo tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2086 matched placebo tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2086 matched placebo tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2086 matched placebo tablets.
Study: NCT06302842

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bioritmon Immuno Defend
Description: Bioritmon Immuno Defend daily oral preparation for 24 days.
Study: NCT05171244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: virtual reality training
Description: training of multisensory processing capacities in virtual reality in addition to usual program of interventions in usual care

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: usual care
Description: usual program of interventions in usual care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: usual care
Description: usual program of interventions in usual care
Study: NCT04907331

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaxzevria
Description: The participants either receive homologous vaccination with Comirnaty or Vaxzevria as approved or the new heterologous vaccination with Vaxzevria followed by Comirnaty

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaxzevria
Description: The participants either receive homologous vaccination with Comirnaty or Vaxzevria as approved or the new heterologous vaccination with Vaxzevria followed by Comirnaty

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty
Description: The participants either receive homologous vaccination with Comirnaty or Vaxzevria as approved or the new heterologous vaccination with Vaxzevria

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comirnaty
Description: The participants either receive homologous vaccination with Comirnaty or Vaxzevria as approved or the new heterologous vaccination with Vaxzevria
Study: NCT05614778

Intervention type: OTHER
Intervention: Zoledronic Acid injection, 5mg/100mL
Description: Zoledronic Acid injection, 5mg/100mL
Study: NCT05509764

Intervention type: DIAGNOSTIC_TEST
Intervention: lung ultrasound score
Description: determination of atelectasis by lung ultrasound score

Intervention type: DIAGNOSTIC_TEST
Intervention: lung ultrasound score
Description: determination of atelectasis by lung ultrasound score

Intervention type: DIAGNOSTIC_TEST
Intervention: lung ultrasound score
Description: determination of atelectasis by lung ultrasound score
Study: NCT05878249

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wound lavage with normal saline
Description: After removing caries and achieving hemostasis after removing caries and achieving hemostasis, wound lavage of the exposed pulp will be done with 5 ml of Normal saline for 30 seconds

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wound lavage with sodium hypochlorite
Description: after removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 5 ml of 2.5% sodium hypochlorite (NaOCl) for 30 seconds,Subsequently the cavity will be flushed with saline for 10 s and blotted dry using sterile cotton pellets

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wound lavage with Ethylenediaminetetraacetic acid(EDTA)
Description: after removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 12% Ethylenediaminetetraacetic acid for 5minutes ,Subsequently, the cavity will be flushed with saline for 10 s and blotted dry using sterile cotton pellets.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wound lavage with sodium hypochlorite followed by Ethylenediaminetetraacetic acid
Description: fter removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 5 ml of 2.5%sodium hypochlorite (NaOCl) for 30 seconds followed by 12%Ethylenediaminetetraacetic acid(EDTA) for 5 minutes.Subsequently, the cavity will be flushed with saline for 10 s and blotted dry using sterile cotton pellets.
Study: NCT05173506

Intervention type: OTHER
Intervention: Computer decision support for physician
Description: The Child Health Improvement through Computer Automation - Child Neurology (CHICA-CN) system will screen patients for needed services and provide reminders to physicians to provide the needed services.

Intervention type: OTHER
Intervention: Computer decision support for physician
Description: The Child Health Improvement through Computer Automation - Child Neurology (CHICA-CN) system will screen patients for needed services and provide reminders to physicians to provide the needed services.

Intervention type: OTHER
Intervention: Computer decision support for physician
Description: The Child Health Improvement through Computer Automation - Child Neurology (CHICA-CN) system will screen patients for needed services and provide reminders to physicians to provide the needed services.

Intervention type: OTHER
Intervention: Computer decision support for physician
Description: The Child Health Improvement through Computer Automation - Child Neurology (CHICA-CN) system will screen patients for needed services and provide reminders to physicians to provide the needed services.
Study: NCT05970783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jincaopian Tablets
Description: Jincaopian Tablets 0.2g tid p.o.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 0.2g tid p.o.
Study: NCT04727242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Hyperthermic intraperitoneal chemotherapy (HIPEC) with gemcitabine. Gemcitabine will be instilled at a dose of 1000 mg/m2 for 60 minutes at temperatures of 42° to 43°C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazine 1000 mg/m2 IV every 3 weeks x 6 cycles given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive Surgery
Description: Surgery for cancer removal

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy (FACT) G questionnaire
Description: Preoperative and Postoperative FACT G questionnaire to assess QoL

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Scan
Description: Radiologic imaging after Cycle 3 and 6 and at each follow up visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Contrast Agent
Study: NCT05524220

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care with a facemask.
Description: The anesthesia provider will supply oxygen via the closed facemask at 10 liters per minute (LPM)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SuperNO2VA™EtCO2 (Nasal Oxygenating Ventilating Apparatus)
Description: The anesthesia provider will attach the SuperNO2VA™ EtCO2 circuit port to the hyperinflation bag with the oxygen flow rate to 10 L/min. The oxygenation, continuous positive airway pressure, and ventilation of the subject will be done via SuperNO2VA™EtCO2 (Nasal Oxygenating Ventilating Apparatus)
Study: NCT05391360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Freethiadine tablets(part I)
Description: Subjects will receive either a single dose of Freethiadine on Day 1 only (SAD HV), twice daily dosing of Freethiadine starting on Day 1 through Day 10 (MAD HV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Freethiadine tablets (part II)
Description: once or twice daily for consecutive 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Freethiadine placebo tablets
Description: Subjects will receive either a single dose of Freethiadine on Day 1 only (SAD HV), twice daily dosing of Freethiadine starting on Day 1 through Day 10 (MAD HV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: entecavir tablets
Description: once daily for consecutive 28 days
Study: NCT04827134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRIUMEQ
Description: TRIUMEQ will be available as fixed dose combination (FDC) dispersible tablets to be administered orally as a dispersion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRIUMEQ
Description: TRIUMEQ will be available as fixed dose combination (FDC) dispersible tablets to be administered orally as a dispersion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOVATO
Description: DOVATO will be available as FDC dispersible tablets to be administered orally as a dispersion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOVATO
Description: DOVATO will be available as FDC dispersible tablets to be administered orally as a dispersion.
Study: NCT06274164

Intervention type: DIAGNOSTIC_TEST
Intervention: Electroencephalography/Polysomnography (EEG/PSG)
Description: Instigators will determine if subjects are candidate for the procedure. A sleep study records the brain electrical waves, the oxygen level in the blood, heart rate breathing, as well as eye and leg movements. Subjects will need to be admitted overnight for the sleep study.

Intervention type: PROCEDURE
Intervention: Skin Biopsy
Description: A special 3-4 mm (0.12 inches) wide circular tool will be used to remove a small section of skin including deeper layers. A numbing cream or injectable anesthetic (i.e. lidocaine) will be applied to the area before the procedure. Sample will be used to create a cell line. This means that investigators would treat the cells from the sample in a way that allows to grow them in the laboratory. Investigators will then use these cells in research.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: A single blood sample of 15 cc (not exceeding 3 cc per kg) (\~3 teaspoons) will be collected for metabolomics (biomarker) study. From available family members, same amount of blood will be obtained to use as a control sample.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: A single blood sample of 15 cc (not exceeding 3 cc per kg) (\~3 teaspoons) will be collected for metabolomics (biomarker) study. From available family members, same amount of blood will be obtained to use as a control sample.
Study: NCT04825860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856 50 mg
Description: Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856 75 mg
Description: Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
Study: NCT04399239

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AuriNovo
Description: AuriNovo is a patient-specific, biologically natural, supportive base for surgical reconstruction of the external ear (auricle) in people born with microtia Grades II-IV. The construct is a 3D-bioprinted collagen hydrogel scaffold encapsulating the patient's own auricular cartilage cells (chondrocytes). The construct is printed in a size and shape that matches the contralateral ear for implantation into the patient.
Study: NCT05501665

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies
Study: NCT06451328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lignosus rhinoceros TM02®
Description: Lignosus rhinoceros TM02®